Updated analysis of EMN02 demonstrated overall survival benefit to early ASCT for multiple myeloma.
作者信息
Garfall Alfred L
机构信息
Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
出版信息
Blood Cancer J. 2025 Jan 3;15(1):1. doi: 10.1038/s41408-024-01198-1.
Abstract
摘要
相似文献
1
Updated analysis of EMN02 demonstrated overall survival benefit to early ASCT for multiple myeloma.EMN02的更新分析表明，早期自体造血干细胞移植对多发性骨髓瘤患者的总生存期有益。
Blood Cancer J. 2025 Jan 3;15(1):1. doi: 10.1038/s41408-024-01198-1.
2
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.挽救性自体干细胞移植对复发多发性骨髓瘤患者总生存期的影响（英国血液与骨髓移植学会/英国骨髓瘤论坛骨髓瘤X复发[强化治疗]最终结果）：一项随机、开放标签的3期试验
Lancet Haematol. 2016 Jul;3(7):e340-51. doi: 10.1016/S2352-3026(16)30049-7.
3
Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment.诱导治疗后达到微小残留病灶不可检测的多发性骨髓瘤患者自体干细胞移植的临床获益。
Cancer Res Commun. 2023 Sep 6;3(9):1770-1780. doi: 10.1158/2767-9764.CRC-23-0185. eCollection 2023 Sep.
4
Response Improvement Rather than Response Status after First Autologous Stem Cell Transplantation Is a Significant Prognostic Factor for Survival Benefit from Tandem Compared with Single Transplantation in Multiple Myeloma Patients.首次自体干细胞移植后反应改善而非反应状态是多发性骨髓瘤患者接受串联移植而非单次移植获得生存获益的重要预后因素。
Biol Blood Marrow Transplant. 2020 Jul;26(7):1280-1287. doi: 10.1016/j.bbmt.2020.03.006. Epub 2020 Mar 16.
5
Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies.来那度胺联合地塞米松与硼替佐米联合地塞米松治疗多发性骨髓瘤的疗效和安全性比较：一项来自随机对照 OCEAN 研究和开放性 HORIZON 研究的长期随访分析。
Clin Lymphoma Myeloma Leuk. 2023 Sep;23(9):687-696. doi: 10.1016/j.clml.2023.05.004. Epub 2023 May 6.
6
Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database.在维持治疗时代，自体干细胞移植序贯治疗对高危骨髓瘤患者无益：来自加拿大骨髓瘤研究组数据库的真实世界研究结果。
Transplant Cell Ther. 2024 Sep;30(9):889-901. doi: 10.1016/j.jtct.2024.06.030. Epub 2024 Jul 4.
7
Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life.自体干细胞移植对老年骨髓瘤患者生命最后一个季度的益处。
Transplant Cell Ther. 2022 Feb;28(2):75.e1-75.e7. doi: 10.1016/j.jtct.2021.09.024. Epub 2021 Oct 6.
8
Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting, 2017.多发性骨髓瘤：2017 年美国血液学会年会的临床更新。
Clin Lymphoma Myeloma Leuk. 2018 May;18(5):321-334. doi: 10.1016/j.clml.2018.02.015. Epub 2018 Mar 1.
9
Relapsed multiple myeloma: who benefits from salvage autografts?复发多发性骨髓瘤：哪些患者从挽救性自体移植中获益？
Intern Med J. 2013 Feb;43(2):156-61. doi: 10.1111/j.1445-5994.2012.02867.x.
10
Tandem autologous stem cell transplantation in elderly patients with myeloma: A multicenter retrospective analysis.老年骨髓瘤患者的串联自体干细胞移植：一项多中心回顾性分析。
Eur J Haematol. 2023 Apr;110(4):444-454. doi: 10.1111/ejh.13922. Epub 2023 Jan 17.
本文引用的文献
1
Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm.无进展生存期作为骨髓瘤临床试验的替代终点：一种不断发展的模式。
Blood Cancer J. 2024 Aug 12;14(1):134. doi: 10.1038/s41408-024-01109-4.
2
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.自体造血干细胞移植对比硼替佐米-美法仑-泼尼松（联合或不联合硼替佐米-来那度胺-地塞米松巩固治疗）以及来那度胺维持治疗用于新诊断的多发性骨髓瘤（EMN02/HO95）：一项多中心、随机、开放标签的3期研究
Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.
Zotero 插件